Muscular Dystrophy (MD) is an X-linked recessive disease affecting mainly boys at a rate of 1 in every 3500 live births. The most common and severe form of the disease is Duchenne Muscular Dystrophy (DMD). The disease is characterized by a relatively rapid wasting of skeletal muscle tissue to a point that leads to paralysis in all patients that suffer from the disease. Unfortunately, due to respiratory or cardiac muscle failure, death occurs in most patients around the age of 30. Currently, the lack of the protein dystrophin is thought to be the chief cause of disease in DMD patients. In addition to a lack of dystrophin, studies are emerging that are painting a picture of a more intricate connection between mitochondrial dysfunction and DMD where increased intracellular and inter-mitochondrial calcium has been shown to cause mitochondrial swelling, loss of mitochondrial membrane integrity, cell death and muscle atrophy. In this article, we will discuss the evidence that places the mitochondrion as a central participant in the etiology of DMD and describe how the relationship between increased intracellular calcium, mitochondrial permeability and dysfunction culminates in muscle loss.

Alzheimer's disease (AD) is a neurodegenerative disorder that is characterized by progressive loss of basal forebrain cholinergic neurons, leading to reduction in transmission through cholinergic fibers involved in processes of attention, learning, and memory. Mitochondria provide and regulate cellular energy and are crucial for proper neuronal activity and survival. Mitochondrial dysfunction is evident in early stages of AD and is involved in AD pathogenesis. This review focuses on the evidence supporting a clear association between amyloid-β toxicity, mitochondrial dysfunction, oxidative stress and neuronal damage/death in Alzheimer's disease. To date, the beta amyloid (Aβ) cascade hypothesis still remains the main pathogenetic model of Alzheimer's disease (AD), but its role in the majority of sporadic AD cases is uncertain. Furthermore, the "mitochondrial cascade hypothesis" could explain many of the biochemical, genetic, and pathological features of sporadic AD. This hypothesis promotes mutations in mitochondrial DNA (mtDNA) as the basis for Alzheimer's disease. The mutations could lead to energy failure, increased oxidative stress, and accumulation of Aβ, which in a vicious cycle reinforces the mtDNA damage and oxidative stress.

The production and secretion of antibodies by human plasma cells (PCs) are two essential processes of humoral immunity. The secretion process relies on a group of proteins known as soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs), which are located in the plasma membrane (t-SNAREs) and in the antibody-carrying vesicle membrane (v-SNARE), and mediate the fusion of both membranes. We have previously shown that SNAP23 and STX4 are the t-SNAREs responsible for antibody secretion. Here, using human PCs and antibody-secreting cell lines, we studied and characterized the expression and subcellular distribution of vesicle associated membrane protein (VAMP) isoforms, demonstrating that all isoforms (with the exception of VAMP1) are expressed by the referenced cells. Furthermore, the functional role in antibody secretion of each expressed VAMP isoform was tested using siRNA. Our results show that VAMP2 may be the v-SNARE involved in vesicular antibody release. To further support this conclusion, we used tetanus toxin light chain to cleave VAMP2, conducted experiments to verify co-localization of VAMP2 in antibody-carrying vesicles, and demonstrated the coimmunoprecipitation of VAMP2 with STX4 and SNAP23 and the in situ interaction of VAMP2 with STX4. Taken together, these findings implicate VAMP2 as the main VAMP isoform functionally involved in antibody secretion.

Background:Systemic lupus erythematosus (SLE) is characterized by the presence of anti-nuclear antibodies (ANAs) in the serum of patients. These antibodies may cross over into the brain resulting in the development of neuropsychiatric symptoms and result in abnormal pathology in other organs such as the heart and kidneys.Objective:The objective of this study was to determine if SLE pathology could be detected in the hearts and brains of rats injected with positive human ANA serum.Materials and Methods:Lewis rats (n = 31) were selected for this study due to documented research already performed with this strain in the investigation of serum sickness, encephalitis and autoimmune related carditis. Rats were injected once a week with either ANA positive or negative control serum or saline. Hearts were examined for initial signs of heart disease including the presence of lipid deposits, vegetation, increased ventricular thickness and a change in heart weight. Brains were examined for the presence of human antibody and necrotic lesions. Animals were observed for outward signs of neuropathy as well. Blood samples were taken in order to determine final circulating concentrations of IgG and monitor histamine levels.Results:Animals injected with ANA were significantly higher for lipid deposits in the heart and an increased ventricular thickness was noted. One animal even displayed Libman-Sacks endocarditis. Brains were positive for the presence of human IgG and diffuse internal lesions occurred in 80% of the ANA positive serum injected animals examined. Blood histamine levels were not significantly different, but actually lower than controls by the end of the experiment.Conclusion:Since human antibodies were detected in the brain, further studies will have to identify which antibody cross reactions are occurring within the brain, examine cell infiltration as well as characterize the antibodies associated with more destructive consequences such as lesion formation.